Brief: Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
05/12/2024 14:28
Dec 5 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O :
* JAZZ PHARMACEUTICALS ANNOUNCES UPDATE TO NATIONAL
COMPREHENSIVE
CANCER NETWORK® (NCCN®) CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
FOR BILIARY TRACT CANCERS TO INCLUDE ZANIDATAMAB-HRII (ZIIHERA®)
* JAZZ PHARMACEUTICALS PLC - ZIIHERA NOW COMMERCIALLY
AVAILABLE IN
THE UNITED STATES
Source text: ID:nPn8Znb5Ya
Further company coverage: JAZZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032